Literature DB >> 29767670

Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor.

S Verstovsek1, V Subbiah2, L Masarova3, C Cameron Yin4, G Tang4, T Manshouri3, E Asatiani5, N G Daver3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29767670      PMCID： PMC6887683          DOI： 10.1093/annonc/mdy173

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  6 in total

Review 1.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

2.  Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophilia.

Authors:  Monica Kasbekar; Valentina Nardi; Paola Dal Cin; Andrew M Brunner; Meghan Burke; Yi-Bin Chen; Christine Connolly; Amir T Fathi; Julia Foster; Molly Macrae; Steven L McAfee; Kristin McGregor; Rupa Narayan; Aura Y Ramos; Tina T Som; Meghan Vartanian; Robb S Friedman; Karim A Benhadji; Gabriela S Hobbs
Journal:  Blood Adv       Date:  2020-07-14

3.  Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.

Authors:  Juan-Carlos Hernández-Boluda; Arturo Pereira; Nienke Zinger; Luuk Gras; Rodrigo Martino; Emmanouil Nikolousis; Jürgen Finke; Anabelle Chinea; Alessandro Rambaldi; Marie Robin; Riccardo Saccardi; Annalisa Natale; John A Snowden; Panagiotis Tsirigotis; Carlos Vallejo; Gerald Wulf; Blanca Xicoy; Domenico Russo; Johan Maertens; Etienne Daguindau; Stig Lenhoff; Patrick Hayden; Tomasz Czerw; Donal P McLornan; Ibrahim Yakoub-Agha
Journal:  Bone Marrow Transplant       Date:  2022-01-23       Impact factor: 5.174

4.  INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.

Authors:  Phillip C C Liu; Holly Koblish; Liangxing Wu; Kevin Bowman; Sharon Diamond; Darlise DiMatteo; Yue Zhang; Michael Hansbury; Mark Rupar; Xiaoming Wen; Paul Collier; Patricia Feldman; Ronald Klabe; Krista A Burke; Maxim Soloviev; Christine Gardiner; Xin He; Alla Volgina; Maryanne Covington; Bruce Ruggeri; Richard Wynn; Timothy C Burn; Peggy Scherle; Swamy Yeleswaram; Wenqing Yao; Reid Huber; Gregory Hollis
Journal:  PLoS One       Date:  2020-04-21       Impact factor: 3.240

Review 5.  Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.

Authors:  Guihong Liu; Tao Chen; Zhenyu Ding; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  Cell Prolif       Date:  2021-03-02       Impact factor: 6.831

6.  Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome.

Authors:  Yun Liu; Baohuan Cai; Yating Chong; Hualei Zhang; Chesley-Anne Kemp; Sumin Lu; Chang-Sheng Chang; Mingqiang Ren; John K Cowell; Tianxiang Hu
Journal:  Cell Death Dis       Date:  2020-10-20       Impact factor: 8.469
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.